Labcorp Holdings Inc. $LH Shares Sold by California State Teachers Retirement System

California State Teachers Retirement System lowered its position in shares of Labcorp Holdings Inc. (NYSE:LH) by 2.4% in the 1st quarter, Holdings Channel reports. The fund owned 120,480 shares of the medical research company’s stock after selling 2,985 shares during the period. California State Teachers Retirement System’s holdings in Labcorp were worth $32,145,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the company. JPL Wealth Management LLC bought a new stake in Labcorp in the 3rd quarter valued at about $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in Labcorp during the 4th quarter valued at about $26,000. Hilton Head Capital Partners LLC bought a new position in Labcorp in the 4th quarter worth about $27,000. Eagle Bay Advisors LLC bought a new position in Labcorp in the 4th quarter worth about $29,000. Finally, DV Equities LLC bought a new position in Labcorp in the 4th quarter worth about $29,000. Institutional investors and hedge funds own 95.94% of the company’s stock.

Labcorp Stock Performance

LH stock opened at $309.47 on Friday. The company has a 50-day simple moving average of $274.71 and a 200 day simple moving average of $271.01. The company has a market capitalization of $25.38 billion, a P/E ratio of 25.60, a PEG ratio of 2.09 and a beta of 0.89. The company has a quick ratio of 1.54, a current ratio of 1.80 and a debt-to-equity ratio of 0.69. Labcorp Holdings Inc. has a fifty-two week low of $244.52 and a fifty-two week high of $316.11.

Labcorp (NYSE:LH) last released its earnings results on Thursday, July 30th. The medical research company reported $4.99 EPS for the quarter, beating the consensus estimate of $4.78 by $0.21. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. The firm had revenue of $3.73 billion for the quarter, compared to analysts’ expectations of $3.71 billion. During the same quarter last year, the company earned $4.35 EPS. Labcorp’s quarterly revenue was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Sell-side analysts predict that Labcorp Holdings Inc. will post 18.04 earnings per share for the current fiscal year.

Labcorp Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 28th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Friday, August 28th. Labcorp’s dividend payout ratio (DPR) is currently 25.51%.

Key Labcorp News

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Labcorp exceeded expectations in the second quarter, reporting adjusted EPS of $4.99 versus the $4.78 analyst consensus and revenue of $3.73 billion versus estimates of $3.71 billion. Revenue increased 5.8% year over year, supported by steady diagnostic-testing demand and growth in drug-development services. Reuters article
• Positive Sentiment: The company raised its 2026 adjusted EPS guidance to $18.10-$18.55, above the roughly $17.99-$18.00 consensus, while forecasting revenue of approximately $14.71 billion-$14.83 billion. Diagnostics Laboratories revenue rose 5.5%, and Biopharma Laboratory Services revenue increased 6.5%. Labcorp second-quarter results
• Positive Sentiment: Labcorp expanded its share-repurchase authorization by $1 billion, repurchased $353.8 million of stock during the quarter and paid $58.7 million in dividends. Truist Financial also raised its price target from $320 to $350 and assigned a “buy” rating, implying further upside from recent levels. Benzinga reference
• Neutral Sentiment: Management highlighted continued investment in oncology, consumer health and technology initiatives. The earnings call transcripts provide additional detail on demand trends, margins and the updated outlook. Labcorp Q2 earnings call transcript
• Negative Sentiment: Despite the earnings and revenue beats, LH shares fell in premarket trading and remain lower in active trading. The reaction indicates that investors may have viewed the results and raised outlook as insufficient relative to elevated expectations and the stock’s recent rally toward its 52-week high. Zacks market reaction
• Negative Sentiment: Recent insider-trading data shows company insiders made multiple sales and no purchases over the past six months, a potential sentiment headwind, although the transactions do not necessarily reflect management’s outlook. Quiver Quantitative report

Insider Activity at Labcorp

In other Labcorp news, EVP Kathryn W. Kyle sold 762 shares of the stock in a transaction on Monday, June 8th. The stock was sold at an average price of $263.89, for a total transaction of $201,084.18. Following the completion of the transaction, the executive vice president directly owned 3,813 shares of the company’s stock, valued at approximately $1,006,212.57. This trade represents a 16.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Adam H. Schechter sold 5,903 shares of Labcorp stock in a transaction on Monday, May 11th. The shares were sold at an average price of $254.50, for a total value of $1,502,313.50. Following the transaction, the chief executive officer owned 107,234 shares in the company, valued at approximately $27,291,053. This trade represents a 5.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 6,991 shares of company stock worth $1,796,696 over the last quarter. 0.84% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on LH. Wall Street Zen raised Labcorp from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Evercore reissued an “outperform” rating and issued a $300.00 price objective on shares of Labcorp in a report on Wednesday, April 8th. Robert W. Baird set a $352.00 target price on Labcorp in a research report on Friday. Morgan Stanley raised their target price on Labcorp from $308.00 to $338.00 and gave the company an “overweight” rating in a research report on Friday. Finally, Bank of America lifted their target price on Labcorp from $300.00 to $320.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $323.27.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.